‌

US Patent 10772972 Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

Patent 10772972 was granted and assigned to Regeneron Pharmaceuticals on September, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Regeneron Pharmaceuticals

Current Assignee

Regeneron Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

September 15, 2020

Patent Application Number

15713569

Date Filed

September 22, 2017

Patent Citations Received

US Patent 11518807 Heavy chain constant regions with reduced binding to Fc gamma receptors

US Patent 11535663 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

US Patent 11542317 Anti-VEGF protein compositions and methods for producing the same

US Patent 11548932 Anti-VEGF protein compositions and methods for producing the same

US Patent 11459373 Anti-VEGF protein compositions and methods for producing the same

US Patent 11459374 Anti-VEGF protein compositions and methods for producing the same

US Patent 11472861 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

US Patent 11485770 Anti-VEGF protein compositions and methods for producing the same

...

Patent Primary Examiner

Karl J Puttlitz

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10772972 Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.